This article is more than 5 years old. Information may no longer be current.

Liraglutide in closed-loop setting effective for decreasing hyperglycemia

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BOSTON — A once-daily injection of liraglutide in the closed-loop setting was effective in decreasing postprandial hyperglycemia, hyperglucagonemia and insulin requirements, according to study findings presented at the American Diabetes Association’s 75th Scientific Sessions.

“This study is one of the first examining the role of liraglutide in the closed-loop system in type 1 diabetes,” Jeniece Trast, RN, CDE, of The Children’s Hospital at Montefiore in Bronx, New York, said during a presentation.

Trast and colleagues conducted an open-labeled crossover design trial that evaluated 15 adults (10 women) with type 1 diabetes for at least 1 year. Participants were assigned Novolog (insulin aspart, Novo Nordisk) plus closed-loop (control) or insulin and subcutaneous injection of 1.2 mg liraglutide (Novo Nordisk) plus closed loop before dinner on the first day.

“We are ... aware of the current limitations of the closed-loop system; postprandial glycemic spikes of over 200 mg/dL and later postprandial hypoglycemia under 70 mg/dL,” Trast said. “These limitations are due to the fact that the current algorithm used in the closed-loop system for calculating the glucose responsive insulin delivery has not responded timely enough to the glucose absorption resulting from the meal.”

Researchers found that the meal-time glycemic profile was better in the liraglutide group compared with the control group (P < .05). Overall delayed time to peak blood glucose levels also was associated with the liraglutide group (P < .0001) compared with the control group. Similarly insulin secretion was less in the liraglutide group compared with the control group (P < .0001).

No significant hypoglycemia events were found in the liraglutide group.

“In conclusion, this was a proof-of-concept study that showed compared to insulin monotherapy in the closed-loop setting, liraglutide plus closed-loop decreases postprandial hyperglycemia [and] hyperglucagonemia and decreases insulin requirements,” Trast said.

Reference:

Trast J, et al. Abstract 220-OR. Presented at: American Diabetes Association’s 75th Scientific Sessions; June 5-9, 2015; Boston.

Disclosure: The researchers report no relevant financial disclosures.